Comparison of post-experimental outcome measures. حسب Neng Pan (5262032)

"…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …"

Schematic representation of the study protocol. حسب Neng Pan (5262032)

Out-of-sample Test Results of the Drop-off Decision Models: (a) ROC Curve of the First Forced Drop-off Decision Models; (b) ROC Curve for Second and More Forced Parking and Drop-of... حسب Fangyi Yang (18867853)

Patient selection flowchart. حسب Aihong Zheng (20571034)

Fig 3 - حسب Aihong Zheng (20571034)

S1 Fig - حسب Aihong Zheng (20571034)

Dynamic stability based on the Feasible Stability Region (FSR). حسب Hyung Suk Yang (20442438)

S2 Fig - حسب Aihong Zheng (20571034)

Fig 4 - حسب Aihong Zheng (20571034)

A particular class of CSR 22Gs are up-regulated in synMuv B mutants. حسب Ashwin Seetharaman (615458)

Demographic structure and Employment categorization. حسب Nehal Mohamed Eisa (21148787)

Burn out assessment throughout demographic structure of the participant. حسب Nehal Mohamed Eisa (21148787)

Stack column chart represent Emotional Exhaustion through demographic structure. حسب Nehal Mohamed Eisa (21148787)

Donut chart shows Demographic structure and Employment categorization. حسب Nehal Mohamed Eisa (21148787)

Stack column chart represent Depersonalization through demographic structure. حسب Nehal Mohamed Eisa (21148787)

Stack column chart represent Personal Accomplishment through demographic structure. حسب Nehal Mohamed Eisa (21148787)

i & ii: PCA represent the (i) 2d and (ii) 3d to identify the underlying dimensions of the lifestyle questions. حسب Nehal Mohamed Eisa (21148787)

Heatmap represents the criterion of health lifestyle survey. (Color guide is provided above each figure). حسب Nehal Mohamed Eisa (21148787)

Health inequalities in the burden of IBD among WCBA. حسب Jiefeng Zhao (9090305)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"